Manipulating the microbial composition is, therefore, an attractive therapeutic approach; probiotics as well as prebiotics have been demonstrated to exert multiple beneficial effects in IBD (186) and T2D (187), including increased GLP-1 release (188). Here, GLP1R is linked to type 2 diabetes mellitus.